Adaptive Phage Therapeutics

  • About APT
  • Contact
  • Careers
  • The Science
  • Pipeline
  • Case Studies
  • News Room
  • Patient Access

News Room

Latest Press Releases

  • Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot OsteomyelitisMay 25, 2022
  • Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical OperationsApril 26, 2022
  • Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action FundApril 4, 2022
  • Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis StudyNovember 2, 2021
  • Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious DiseasesSeptember 30, 2021
  • Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal OfficerSeptember 23, 2021
  • Adaptive Phage Therapeutics Adds Jesse L. Goodman, M.D., M.P.H., to its Board of DirectorsSeptember 14, 2021
  • Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a ChildSeptember 9, 2021
  • Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of ResearchAugust 31, 2021

See all press releases

Get to know us

Featured Stories

Company Fact sheet

Adaptive Phage Therapeutics

  • About APT
  • Contact
  • Careers
  • The Science
  • Pipeline
  • Case Studies
  • News Room
  • Patient Access
  • LinkedIn
  • Twitter
  • Email
  • Job Board
  • Directory